FHI Clinical Inc., has announced its intent to acquire Triclinium Clinical Development Proprietary Limited, a full-service CRO and South African-based subsidiary of EOH. The deal results in FHI employing over 425 employees across 12 countries.

TCD has contracts from both large pharma and small biotech firms across a spectrum of therapeutic areas including infectious disease studies with malaria and HIV and has a history of expertise in tuberculosis trials.

“TCD’s experience and credibility in the South African market, marked by long-term client relationships and follow-on business, is a fit for our strategic vision,” said Ted FitzGerald, FHI Clinical CEO. “In addition to therapeutic alignment as an infectious disease CRO, TCD also provides the opportunity to expand our organizational ability to conduct trials in low- and middle-income countries better positioning us to repeat that success anywhere in the world.”